517 Identification and characterization of selective MELK kinase inhibitors
Patrizia Carpinelli, Arturo Galvani(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Dario Ballinari(Nerviano Medical Sciences), Rossella Galli(IRCCS Ospedale San Raffaele), Ulisse Cucchi, D. Donati, Eduard Felder, Stefania Re Depaolini(Nerviano Medical Sciences), Marco Caruso(University of Catania), Giulia Canevari(Nerviano Medical Sciences), A. Montagnoli(Technion – Israel Institute of Technology), Nadia Amboldi(University of Pavia)
Cited by 0
Related Papers
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors
|Cancer Cell|2005|1.3k
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
|Genes & Development|1999|611
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205